AB Biosciences

AB Biosciences

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

AB Biosciences is a specialized antibody engineering and production company serving the global research and drug discovery community. Founded in 2007 and based in San Diego, it focuses on creating niche antibody reagents and tools that are not widely available from larger suppliers. Its business model appears to be service and product-based, catering primarily to academic, biotech, and pharmaceutical researchers. The company emphasizes next-day shipping, indicating a commercial, revenue-generating operation with a direct-to-consumer e-commerce platform.

AntibodiesBiologics

Technology Platform

Antibody engineering and production platform for creating niche and custom antibody molecules, enabling rapid turnaround for research and drug discovery applications.

Opportunities

The growing global demand for specialized research tools and early-stage therapeutic antibody discovery services presents a significant opportunity.
Expansion into new antibody formats (e.g., bispecifics, nanobodies) and deepening relationships with biopharma clients could drive further growth.
The company's global e-commerce reach allows it to capitalize on international biotech growth.

Risk Factors

Competition from larger reagent companies expanding into custom services and from agile startups poses a threat.
Operational risks include maintaining quality and rapid delivery across a global supply chain.
The business is also sensitive to downturns in research and biotech funding, which could reduce demand for custom services.

Competitive Landscape

AB Biosciences competes in a fragmented market that includes large catalog reagent suppliers (e.g., Thermo Fisher, Abcam), specialized antibody boutiques, and CROs offering discovery services. Its differentiation lies in focusing on niche, hard-to-find antibodies and emphasizing speed and customization, areas often underserved by larger players. It must continually innovate to stay ahead of both broad and niche competitors.